Infinity Pharmaceuticals Inc.
INFI
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $726,089.00 |
|---|---|
| Enterprise Value | $-8,110,911.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.48 |
| Beta | 1.38 |
| Outstanding Shares | 89,885,492 |
Return
| Return on Equity | 108.35% |
|---|---|
| Return on Assets | -190.90% |
| Return on Invested Capital | -458.62% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | -3.16 |
| Enterprise Value to EBIT | 0.19 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -1.1 |
| Debt to Equity | -0.24 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Infinity Pharmaceuticals Inc.
CEO: Adelene Perkins Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policies and drug pricing legislation, which are the most critical factors for industry profitability.
Determines the exact funding levels for the FDA and NIH, which dictates the speed of drug reviews and the availability of research grants.
Directly oversees the FDA and NIH; this is the primary regulatory body for drug approvals, clinical trials, and research funding.
Oversight of patent law and antitrust is critical; IP protection and generic competition regulations are the primary drivers of pharmaceutical valuations.
Frequently holds high-profile hearings on drug pricing and pharmaceutical industry practices, creating significant headline and regulatory risk.
The VA is one of the largest purchasers of pharmaceutical products in the U.S.; its drug formulary decisions directly impact revenue.